CoChat
Sign Up
Cited by 25Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesFerroptosis and cancer prognosis

Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer

Open access
Zhou, Xueliang, Lin, Joshua, Shao, Yanfei, Zheng, Huang, Yang, Yi, Li, Shuchun, Fan, Xiaodong, Hong, Hiju +4 more·2024·International Journal of Biological Sciences
DOI 10.7150/ijbs.98200PMC PMC11528457
Open this paper in CoChat — free account

Abstract

In summary, we have identified for the first time that PLCG2 could be considered a precise biomarker and promising therapeutic target for predicting CRC prognosis, optimizing individualized treatment, reversing CRC immune escape, and overcoming resistance to ICB therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/ijbs.98200

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Prior studies have shown contradictory findings with respect to the role of PLCG2 in proliferation and apoptosis.

    “Prior studies have shown contradictory findings with respect to the role of PLCG2 in proliferation and apoptosis.”

    From Alzheimer's disease–associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell–derived microglia‐like cells (2025) · cites this paper as [50]

    The Discussion (page unavailable) summarizes prior work on PLCG2 in several cancers but does not describe contradictory findings on proliferation or apoptosis. The Results report this paper’s own findings that PLCG2 promotes proliferation and inhibits apoptosis in colorectal cancer cells. Searches for conflicting or opposing prior findings found no passage addressing the claimed contradiction. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 44

  1. [1]Bray F Laversanne M Sung H Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2024 74 229 263 38572751
  2. [2]Delattre JF Selcen Oguz Erdogan A Cohen R Shi Q Emile JF Taieb J A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification Cancer Treat Rev 2022 103 102325 34954486
  3. [3]Wu CC Wang JH Lin PC Liang CA Huang CY Lien HC Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis Crit Rev Oncol Hematol 2020 145 102823 31783291
  4. [4]Katan M Cockcroft S Phospholipase C families: Common themes and versatility in physiology and pathology Prog Lipid Res 2020 80 101065 32966869
  5. [5]Jackson JT Mulazzani E Nutt SL Masters SL The role of PLCgamma2 in immunological disorders, cancer, and neurodegeneration J Biol Chem 2021 297 100905 34157287 PMC8318911
  6. [6]Gango A Alpar D Galik B Marosvari D Kiss R Fesus V Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib Int J Cancer 2020 146 85 93 31180577
  7. [7]Yang Y Yang Y Huang H Song T Mao S Liu D PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration Cell Death Dis 2023 14 257 37031207 PMC10082821
  8. [8]Li Z Zhao R Yang W PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma Medicine (Baltimore) 2021 100 e25008 33725976 PMC7982206
  9. [9]Cortés-Ciriano I Gulhan DC Lee JJ Melloni GEM Park PJ Computational analysis of cancer genome sequencing data Nat Rev Genet 2022 23 298 314 34880424
  10. [10]Liao Y Yang Y Zhou G Anoikis and SPP1 in idiopathic pulmonary fibrosis: integrating bioinformatics, cell, and animal studies to explore prognostic biomarkers and PI3K/AKT signaling regulation Expert Rev Clin Immunol 2024 20 679 693 38318669
  11. [11]Mayakonda A Lin DC Assenov Y Plass C Koeffler HP Maftools: efficient and comprehensive analysis of somatic variants in cancer Genome Res 2018 28 1747 1756 30341162 PMC6211645
  12. [12]Wang F Long J Li L Single-cell and spatial transcriptome analysis reveals the cellular heterogeneity of liver metastatic colorectal cancer Sci Adv 2023 9 eadf5464 37327339 PMC10275599
  13. [13]Sui S An X Xu C An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer Theranostics 2020 10 11938 11949 33204321 PMC7667685
  14. [14]Zhang X Zeng B Zhu H Role of glycosphingolipid biosynthesis coregulators in malignant progression of thymoma Int J Biol Sci 2023 19 4442 4456 37781041 PMC10535712
  15. [15]Zhou X Aikemu B Li S Shao Y Jia H Huang L Comprehensive exploration of tumor immune microenvironment feature and therapeutic response in colorectal cancer based on a novel immune-related long non-coding RNA prognostic signature Front Genet 2022 13 962575 36092924 PMC9454821
  16. [16]Xu H Li YF Yi XY Zheng XN Yang Y Wang Y ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression Mil Med Res 2023 10 64 38082365 PMC10714548
  17. [17]Shi D Wu X Jian Y Wang J Huang C Mo S USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer Nat Commun 2022 13 5644 36163134 PMC9513055
  18. [18]He X Chen H Zhong X Wang Y Hu Z Huang H BST2 induced macrophage M2 polarization to promote the progression of colorectal cancer Int J Biol Sci 2023 19 331 45 36594082 PMC9760448
  19. [19]Chan JM Quintanal-Villalonga A Gao VR Xie Y Allaj V Chaudhary O Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer Cancer Cell 2021 39 1479 96 e18 34653364 PMC8628860
  20. [20]Li WQ Hu N Wang Z Yu K Su H Wang L Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population PLoS One 2013 8 e68999 23874846 PMC3715462
  21. [21]Fei M Lu C Feng B Sun J Wang J Sun F Bioinformatics analyses and experimental validation of the role of phagocytosis in low-grade glioma Environ Toxicol 2024 39 2182 96 38112449
  22. [22]Qi F Qin WX Zang YS Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways Oncol Lett 2019 17 2905 14 30854067 PMC6365902
  23. [23]Zhang H Qin C Gan H Guo X Zhang L Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer Front Genet 2020 11 499 32508884 PMC7253627
  24. [24]Bonfiglio S Sutton LA Ljungstrom V Capasso A Pandzic T Westrom S BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib Blood Adv 2023 7 2794 806 36696464 PMC10279547
  25. [25]Xiao Y Rabien A Buschow R Amtislavskiy V Busch J Kilic E Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma Cancer Res 2020 80 5491 501 33115803
  26. [26]Feng A TZ Yin B The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer Oncotarget 2016 7 20507 19 26840258 PMC4991471
  27. [27]Moncayo G Grzmil M Smirnova T Zmarz P Huber RM Hynx D SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment Neuro Oncol 2018 20 621 31 29401256 PMC5892144
  28. [28]Buttarelli M Ciucci A Palluzzi F Raspaglio G Marchetti C Perrone E Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients J Exp Clin Cancer Res 2022 41 50 35120576 PMC8815250
  29. [29]Stanislaus A Bakhtiar A Salleh D Tiash S Fatemian T Hossain S Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel Cancer Cell Int 2012 12 30 22709569 PMC3407783
  30. [30]Wiese W Barczuk J Racinska O PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities Cancers (Basel) 2023 15 5297 37958470 PMC10648005
  31. [31]Zuo Y Zhang CZ Ren Q Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression Phytomedicine 2022 99 154015 35278901
  32. [32]Panneerpandian P Ganesan K PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors Med Oncol 2023 40 120 36934368
  33. [33]Yu JR Liu YY Gao YY Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway J Ethnopharmacol 2024 324 117791 38301987
  34. [34]Suwa T Kobayashi M Nam JM Harada H Tumor microenvironment and radioresistance Exp Mol Med 2021 53 1029 35 34135469 PMC8257724
  35. [35]de Visser KE Joyce JA The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth Cancer Cell 2023 41 374 403 36917948
  36. [36]Clara JA Monge C Yang Y Takebe N Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update Nat Rev Clin Oncol 2020 17 204 32 31792354
  37. [37]McLaughlin M Patin EC Pedersen M Inflammatory microenvironment remodelling by tumour cells after radiotherapy Nat Rev Cancer 2020 20 203 217 32161398
  38. [38]Wang ZH Peng WB Zhang P Yang XP Zhou Q Lactate in the tumour microenvironment: From immune modulation to therapy EBioMedicine 2021 73 103627 34656878 PMC8524104
  39. [39]Zhang Y Zhang Z The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Cell Mol Immunol 2020 17 807 21 32612154 PMC7395159
  40. [40]Andre T Shiu KK Kim TW Jensen BV Jensen LH Punt C Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer N Engl J Med 2020 383 2207 18 33264544
  41. [41]Andre T Amonkar M Norquist JM Shiu KK Kim TW Jensen BV Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial Lancet Oncol 2021 22 665 77 33812497
  42. [42]Diaz LA Jr Shiu KK Kim TW Jensen BV Jensen LH Punt C Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Lancet Oncol 2022 23 659 70 35427471 PMC9533375
  43. [43]Ganesh K Optimizing immunotherapy for colorectal cancer Nat Rev Gastroenterol Hepatol 2022 19 93 4 34907331 PMC9487162
  44. [44]Ganesh K Stadler ZK Cercek A Mendelsohn RB Shia J Segal NH Immunotherapy in colorectal cancer: rationale, challenges and potential Nature Reviews Gastroenterology & Hepatology 2019 16 361 75 30886395 PMC7295073

Cited by

Sorted by citations

Authors
Zhou, X., Lin, J., Shao, Y., Zheng, H., Yang, Y., Li, S., Fan, X., Hong, H., Mao, Z., Xue, P., Zhang, S., & Sun, J.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
Sun, Jing
ORCID
Venue
International Journal of Biological Sciences
Publisher
Ivyspring International Publisher
Published
2024
Volume
20
Issue
14
Pages
5548-5575
ISSN
1449-2288 (ISSN-L)
DOI
10.7150/ijbs.98200
PMC
PMC11528457
OpenAlex
W4403545785
Cited by
25
References
0
Citations by year
2026: 15 · 2025: 9 · 2024: 1
FWCI
4.28
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • International Journal of Biological Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
Keywords
PLCγ2, colorectal cancer, tumor immune microenvironment, immune checkpoint blockade, immune evasion, tumor progression, prognostic factors, therapeutic target
MeSH terms
Immune Checkpoint Inhibitors, Animals, Female, Humans, Male, Prognosis, Colorectal Neoplasms, Disease Progression, Cell Line, Tumor, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review